AVALA RES
Research AVALA RES (CVJ) on Bullrun: market cap EUR 830.30K, P/E 0.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerCVJ
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyEUR
- Market capEUR 830.30K
- P/E0.1
- Financial periodFY2024
- RevenueAUD 15.37M
- Revenue growth11.6%
- Net income-AUD 51.24M
- Free cash flow-AUD 17.69M
- Gross margin100.0%
Valuation Snapshot
latest market cap is EUR 830.30K; P/E is 0.1.
Peer valuation comparison
Latest P/E is 0.05x versus a Healthcare sector median of 24.46x (99.8% below).
Latest P/E is 0.05x versus a Australia median of 16.97x (99.7% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | AUD 15.37M | -AUD 51.24M | -AUD 17.69M | 100.0% | -0.11 | AUD 1.64M | AUD 72.47M | AUD 13.92M |
| FY2023 | AUD 13.78M | -AUD 33.79M | -AUD 25.94M | 100.0% | -0.09 | AUD 765.00K | AUD 60.97M | AUD 59.26M |
| FY2022 | AUD 6.41M | -AUD 26.47M | -AUD 65.60M | 100.0% | -0.07 | AUD 1.91M | AUD 47.17M | AUD 84.90M |
| FY2021 | AUD 4.29M | -AUD 25.10M | -AUD 37.10M | 98.9% | -0.09 | AUD 3.11M | AUD 680.00K | AUD 91.87M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-17 | EUR 830.30K | 0.1 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About AVALA RES
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is AVALA RES's market cap?
AVALA RES's market capitalization is EUR 830.30K.
What is AVALA RES's P/E ratio?
AVALA RES's price-to-earnings (P/E) ratio is 0.1.
What does AVALA RES do?
Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivation, manufacture, and sale of medicinal cannabis in Australia and Europe. Its product portfolio includes the Satipharm delivery system for cannabinoids. The company was founded in 2014 and is based in Mildura, Australia.